News Release

Journal Article Cites HemoVoid™ in Multi-Omics Analysis of Red Blood Cells in Thalassemia

MONMOUTH JUNCTION, NJ , March 6, 2025 -- Biotech Support Group reports on a research article describing the simplicity and efficiency of their HemoVoid™ technology for enriching erythrocyte low abundance proteins, in order to assess dysregulated pathways associated with Thalassemia severity. 

The citation is:

Mitra, Nibedita, et al. " Multi-Omics Analysis of Red Blood Cells Reveals Molecular Pathways Underlying Thalassemia Severity Beyond Globin Gene Mutations ." medRxiv (2025): 2025-02.

Hemoglobinopathies are the most common monogenic genetic disorders. Clinical severity other than mutational effects are still unknown. This study aims to identify dysregulated molecular pathways in red blood cells contributing to thalassemia severity. In the Methods section for Sample Preparation for RBC Proteomics Study, the article states “A 75µL suspension of RBC cells was used to prepare RBC lysate. Proteins were extracted with RIPA buffer, and hemoglobin was depleted using the HemoVoid kit”. A total of 430 differentially abundant proteins were identified between the two patient groups. The critical protein signatures and their target pathways are as follows: 1. Increased PIP4K2A Proteins: This leads to a reduction in gamma globin levels. 2. Altered Expression of snRNA/snRNP Complex HEXIM1 and Other snRNPs (SNRNP70, SF3B4, WDR77): These changes impact transcription, translation, and aberrant splicing 3. Reduced Levels of Functional Autophagy Regulatory Proteins (ATG2B, ATG4B, ATG5, FOXO3). 4. Decreased Abundance of Functional Hsp70 Heat Shock Chaperone Proteins (HSPA2, HSPA14). 5. Increased Levels of Iron Regulatory Proteins (FTH1, FTL) in TDT Patients. 

“It’s very rewarding to see that for Hemoglobin removal, HemoVoid™ was an essential product to enrich the red blood cell proteome for this study. Many references now validate the use of HemoVoid™ as an efficient method to deplete Hemoglobin in order to enrich and analyze low abundance sub-proteomes.”, states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

For more information on HemoVoid™, visit:

http://www.biotechsupportgroup.com/HemoVoid-Hemoglobin-Depletion-From-Erythrocytes-p/hvk.htm

For more information of all of our Hemoglobin removal products, visit:

https://www.biotechsupportgroup.com/Hemoglobin-Removal-s/312.htm

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for expanding proteomic analysis. Following a tiered business strategy, the company continues its growth in the consumable research products area. For this market, key products include: AlbuVoid™ and AlbuSorb™ PLUS for albumin & IgG depletion, Cleanascite ™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NRicher™ for low abundance, family specific, and targeted proteome enrichment. For more information, go to http://www.biotechsupportgroup.com

For business development contact: Matthew Kuruc
732-274-2866 mkuruc@biotechsupportgroup.com

Keywords

Thalassemia, RBC lysates, Hemoglobin depletion, erythrocyte proteomics, HemoVoid™